Font Size

SCREEN

Profile

Direction

Menu Style

About AVG - Overview

The isirv Antiviral Group (isirv-AVG) is a Special Interest Group of isirv and as such the Group’s status, as an independent professional scientific body, and the rules governing its activities are those pertaining to isirv.  It was established following the merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv.

The mission of the Group encompasses that of isirv in promoting understanding of the means of prevention, treatment and control of influenza and other respiratory virus diseases.

In addition to their use in reducing the impact of influenza epidemics, and in the treatment of severe respiratory disease, antivirals provide the first line of defence in an influenza pandemic, prior to the availability of vaccines, as in 2009.

The AVG’s specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals.  

Principal activities and areas of interest of the AVG are listed under members’ interests.

A panel of influenza viruses resistant to neuraminidase inhibitors is available from isirv-AVG.

Antiviral Group Reports can be found below:

2012-2013
2013-2014


Meetings and Workshops

The intention is to organise one international meeting or workshop each year. Initially the topics for meetings have had a regional focus.  

The first AVG Conference on Influenza Antivirals: Efficacy and Resistance, with a focus on Latin America, was held in Rio de Janeiro, Brazil, on 8-10 November 2011, and was co-organised with the Oswaldo Cruz Foundation (FIOCRUZ). 

The second AVG Conference on Severe Influenza: Burden, Pathogenesis and Management, with a focus on South East Asia, took place in Hanoi, Viet Nam, on 29-31 October 2012, and was co-organised with The National Institute of Hygiene and Epidemiology (NIHE).

 

An AVG-GISAID Workshop, on Sequence Analysis and Detection of Antiviral Resistance, co-organised with GISAID and WHO, was held during Options VIII in Cape Town, South Africa, on 7 September 2013.

 

An AVG Discussion Meeting on Clinical Trial Endpoints for Studies of Antivirals in Hospitalised and At-Risk Influenza Patients was held during Options VIII in Cape Town, on 8 September 2013.

 

The third AVG Conference on Influenza and other Respiratory Virus Infections: Advances in Clinical Management, with a focus on the effective use of antivirals and vaccines to combat influenza in Japan, was held in Tokyo, Japan, on 4-6 June 2014.

A workshop on Next Generation Sequencing of Viruses, co-organised with GISAID and the PREDEMICS Consortium, was held at the Pasteur Institut, Paris, France, on 20-21 May 2015.

The fourth AVG Conference on Novel Antiviral Therapies for Influenza and other Respiratory Viruses: Bench to Bedside, with a focus on recent advances in the development of antivirals against respiratory viruses, was held at the University of Texas, Austin, Texas, USA, on 2-4 June 2015.

isirv avg logo

avg stack